ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
    4.
    发明公开
    ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS 审中-公开
    VERBESSERUNG DER ANTIKREBSWIRKUNG VON免疫调节剂FC-FUSIONSPROTEINEN

    公开(公告)号:EP2925350A1

    公开(公告)日:2015-10-07

    申请号:EP13811698.3

    申请日:2013-12-03

    IPC分类号: A61K39/00 A61P35/00 C07K16/28

    摘要: The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method and its use in treating a subject afflicted with a cancer or a disease caused by an infectious agent.

    摘要翻译: 本公开提供了一种增强Fc融合蛋白的抗肿瘤功效的方法,其特异性结合靶基因,例如配体的共抑制或共刺激受体,在患有癌症的受试者的T细胞上 或由感染因子引起的疾病并改变免疫调节靶的活性,从而增强针对癌细胞或感染因子的内源性免疫应答,其中所述方法包括选择,设计或修饰Fc融合蛋白的Fc区 以增强所述Fc区与活化Fc受体(FcR)的结合。 本公开还提供了通过所述方法产生的Fc融合蛋白,其具有增强受试者中癌症或感染因子的细胞的内源性免疫应答的增强能力。 本公开进一步提供了治疗受试者的方法,其包括向受试者施用治疗有效量的Fc融合蛋白,其中已经选择,设计或修饰了Fc融合蛋白的Fc区,以增加所述Fc融合蛋白的结合 Fc区到激活的FcR。